30 years’ experience working with and developing recombinant human albumin based products and technologies

Albumedix has a world leading position within recombinant albumin engineering, microbial expression and large scale manufacturing. With 30 years’ accumulated knowledge from the biopharmaceutical industry, Albumedix is the company to go to for recombinant albumin related drug delivery and formulation solutions.

Albumedix was established in 2016 as an independent company fully owned by Novozymes A/S. The company was created by separating the biopharmaceutical activities of Novozymes out into an independent company. These activities have been based in part on an acquisition by Novozymes A/S of Delta Biotechnology in Nottingham, UK from Sanofi Aventis in 2006.
Prior to 2006, Delta Biotechnology was owned by different companies after the establishment by Bass Plc in 1984.

Albumedix has ongoing commercial business based on sales of Recombumin®, recombinant albumin for drug formulation as well as license agreements for Veltis®, albumin based drug delivery platform.  

As an example, in 2006 Merck & Co. started to use Recombumin® in their M-M-R® II vaccine for immunization against measles, mumps and rubella virus infections in children 12 months through 12 years of age. Since then more than 70 million doses haven been administered worldwide and Merck & Co. are now also using Recombumin® in their ProQuad® vaccine.

The first drug to use Albumedix’ Veltis® half-life extension technology was launched by GlaxoSmithKline in 2014 as Tanzeum® (US) and Eperzan® (EU). Tanzeum® is a GLP-1 fusion to recombinant albumin for once weekly treatment of type 2 diabetic patients.


Send now




Next event

Antibody Engineering & Therapeutics (1)

Meet up with Albumedix at the 2017 Antibody Engineering & Therapeutics